TD Cowen Forecasts Strong Price Appreciation for Medpace (NASDAQ:MEDP) Stock

Medpace (NASDAQ:MEDP) had its price objective upped by analysts at TD Cowen from $492.00 to $673.00 in a report issued on Friday, Benzinga reports. The firm currently has a “hold” rating on the stock. TD Cowen‘s price objective indicates a potential upside of 3.32% from the company’s previous close.

MEDP has been the subject of a number of other research reports. BMO Capital Markets boosted their price target on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Weiss Ratings raised shares of Medpace from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Royal Bank Of Canada increased their price objective on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Mizuho raised their target price on shares of Medpace from $665.00 to $700.00 and gave the company an “outperform” rating in a report on Wednesday, October 7th. Finally, UBS Group assumed coverage on shares of Medpace in a report on Wednesday, September 30th. They issued a “neutral” rating and a $673.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $628.73.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $651.39 on Friday. The company has a market capitalization of $18.18 billion, a P/E ratio of 38.05, a P/E/G ratio of 2.96 and a beta of 1.18. Medpace has a 1 year low of $373.00 and a 1 year high of $684.52. The business’s 50 day simple moving average is $609.84 and its 200 day simple moving average is $536.74.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, October 21st. The company reported $4.84 earnings per share for the quarter, beating the consensus estimate of $4.44 by $0.40. The firm had revenue of $716.00 million during the quarter, compared to analysts’ expectations of $714.47 million. Medpace had a return on equity of 104.17% and a net margin of 18.24%. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.86 EPS. On average, sell-side analysts anticipate that Medpace will post 17.54 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO August Troendle sold 49,018 shares of the stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $628.11, for a total value of $30,788,695.98. Following the completion of the transaction, the chief executive officer owned 433,372 shares of the company’s stock, valued at approximately $272,205,286.92. This represents a 10.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 336,140 shares of company stock worth $208,008,328 over the last three months. 20.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Medpace

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in Medpace during the 2nd quarter worth approximately $1,323,047,000. Madison Asset Management LLC acquired a new stake in Medpace in the second quarter valued at approximately $128,956,000. Bank of America Corp DE acquired a new stake in Medpace in the second quarter valued at approximately $116,891,000. American Capital Management Inc. acquired a new stake in shares of Medpace during the 2nd quarter valued at $111,329,000. Finally, Caisse de depot et placement du Quebec bought a new stake in shares of Medpace during the second quarter worth about $80,979,000. 77.98% of the stock is owned by institutional investors.

More Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Raised 2026 outlook: Medpace now expects full-year EPS of $17.97–$18.32, above the $17.68 analyst consensus. Revenue guidance of $2.8–$2.9 billion is also at or above expectations. Medpace forecasts 2026 EPS and buyback
• Positive Sentiment: Quarterly results exceeded expectations: Third-quarter EPS was $4.84 versus the $4.44 consensus, while revenue rose 8.5% year over year to $716 million, slightly ahead of forecasts. Net margin was 18.24%. Medpace third-quarter 2026 results
• Positive Sentiment: Demand indicators remained healthy: Third-quarter net new business awards reached $873 million, and ending backlog grew 5.6% year over year to $3.2 billion, supporting future revenue visibility. Medpace three key takeaways
• Positive Sentiment: $1 billion buyback: The new authorization replaces the prior program and signals management confidence while potentially supporting per-share results. Medpace buyback and third-quarter profit
• Neutral Sentiment: Deutsche Bank raised its price target to $650 from $535 but retained a Hold rating, indicating improved fundamentals may already be reflected in the share price. Deutsche Bank Medpace price target
• Negative Sentiment: Investors remain concerned that Medpace is expensive, with commentary suggesting the stock may be about 24% overvalued. Those concerns help explain why the shares decreased even after the earnings beat and raised outlook. Medpace valuation analysis

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.